Search Result "internal tandem duplication (ITD) of t"
Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/ Refractory Acute Myeloid Leukemia
Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 18 Issue: 10 Year: 2018 Page: 1489-1494
Author(s): Nan Yang,Zhenyang Gu,Zhanxiang Liu,Wenrong Huang,Shuhong Wang,Lili Wang,Chunji Gao
Membrane Tyrosine Kinase Receptors are an Important Target for the Therapy of Acute Myeloid Leukemia
Journal: Current Cancer Therapy Reviews
Volume: 4 Issue: 1 Year: 2008 Page: 31-49
Author(s): Ugo Testa
Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Journal: Current Cancer Therapy Reviews
Volume: 9 Issue: 3 Year: 2013 Page: 181-219
Author(s): Ugo Testa
State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies
Journal: Current Medicinal Chemistry
Volume: 19 Issue: 28 Year: 2012 Page: 4875-4884
Author(s): G. Zauli,R. Voltan,V. Tisato,P. Secchiero
Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia
Journal: Current Pharmaceutical Design
Volume: 10 Issue: 1 Year: 2004 Page: 1867-1883
Author(s): Dirk Schmidt-Arras, Joachim Schwable, Frank- D. Bohmer, Hubert Serve
Implications of FLT3 Mutations in the Therapy of Acute Myeloid Leukemia
Journal: Reviews on Recent Clinical Trials
Volume: 2 Issue: 2 Year: 2007 Page: 135-141
Author(s): Ryan J. Mattison, Kelly R. Ostler, Frederick L. Locke, Lucy A. Godley
FLT3 as a Therapeutic Target in Childhood Acute Leukemia
Journal: Current Drug Targets
Volume: 8 Issue: 6 Year: 2007 Page: 703-714
Author(s): Matthew C. Stubbs, Scott A. Armstrong
Acute Myeloproliferative Disease
Ebook: Physiopathogenesis of Hematological Cancer
Volume: 1 Year: 2012
Author(s): Eduardo Magalhaes Rego,Mariana Tereza de Lira Benicio
Doi: 10.2174/978160805259211201010201
Bench to Bedside Targeting of FLT3 in Acute Leukemia
Journal: Current Drug Targets
Volume: 11 Issue: 7 Year: 2010 Page: 781-789
Author(s): Keith W. Pratz, Mark J. Levis
Second-Generation Protein Kinase Inhibitor â A Focus on Quizartinib, A Promising Targeted Therapy for High-Risk FLT3+ Patients with Acute Myeloid Leukemia
Ebook: Frontiers in Clinical Drug Research - Anti-Cancer Agents
Volume: 5 Year: 2019
Author(s): Xavier Thomas,Etienne Paubelle
Doi: 10.2174/9789811405150119050003